The efficacy and safety of pro-yellow laser treatment for the management of vascular skin lesions was reported in study data published in the Journal of Cosmetic Dermatology.

In a study of patients with myriad vascular skin conditions, treatment with 577-nm pro-yellow laser was associated with substantial improvement in lesion size and appearance. Treatment was well tolerated by all patients.

Although pro-yellow laser is an established treatment method for diabetic retinopathy, only a limited number of studies have evaluated its efficacy and safety for the management of vascular skin lesions. To close this gap, investigators retrospectively assessed the outcomes of patients who received treatment with a pro-yellow laser at a dermatology clinic in Turkey.


Continue Reading

Patients with a clinical diagnosis of any vascular skin condition were eligible for inclusion; their demographic data and clinical history were extracted from medical records. All patients received treatment with the same laser apparatus at 4-week intervals.

Treatment efficacy was assessed through clinical examination performed at baseline and 4 weeks after the last laser session. Improvement was rated by clinicians on an ordinal scale based on level of lesion improvement: “excellent” (75% to 100% improved), “very good” (50% to 74%), “good” (25% to 49%), and “poor” (less than25%). Adverse events were catalogued and reported.

A total of 74 patients received pro-yellow laser treatment at the participating dermatology clinic. Their mean age was 40.97±7.77 years and the majority (71.6%) were women. Patient skin phototypes ranged from Fitzpatrick type 2 (45.9%) to type 3 (54.1%). Various vascular skin conditions were represented in the cohort, including facial telangiectasia (n=37), erythematotelangiectatic rosacea (n=13), port-wine stain (n=6), spider angioma (n=6), venous lake (n=6), cherry angioma (n=4), and scrotal angiokeratoma (n=2).

The mean number of laser sessions varied by diagnostic group, and ranged from 1 to 3.33. Very good to excellent improvement was observed in the majority of the study cohort. Among patients with facial telangiectasia, 70.3% and 29.7% experienced excellent or very good improvement, respectively. In patients treated for rosacea, 46.2% experienced excellent improvement, 46.2% experienced very good improvement, and 7.6% experienced good improvement. In patients with venous lake, results were evenly divided between excellent (50%) and very good (50%) improvement. All patients with cherry angioma, spider angioma, and scrotal angiokeratoma experienced excellent improvement following laser treatment.

The only reported adverse event was erythema in the treatment area, which resolved within 24 to 48 hours of laser application.

Treatment efficacy was not significantly associated with patient age, sex, or skin phototype.

Based on these results, pro-yellow laser is an effective, safe option for the management of vascular skin lesions. However, because the trial did not enroll patients with severe vascular problems, results cannot be extrapolated to more serious lesions.

“[The] pro-yellow laser provides efficient results without side effects like edema, petechia and purpura,” investigators wrote. “The pro-yellow device is small, compact, user friendly and has [an] integrated cooling system [and] these features make it practical for daily use in dermatology clinics.”

Reference

Aksoy Sarac G, Onder M. Evaluation of the efficacy of pro-yellow laser in the management of vascular skin disorders. J Cosmet Dermatol. Published online April 19, 2021. doi:10.1111/jocd.14162

This article originally appeared on Dermatology Advisor